Deficiency of NFE2L1 causes a unique phenotypic switch in the TAMs from its pro‐cancer M2‐type to another anti‐cancer M1‐type, thereby inhibiting malignant progression of glioma. This evidence concerns the gene NFE2L1 and central nervous system cancer.